Methyldopa for Reduction of DQ8 Antigen Presentation in At-Risk Subjects for Type 1 Diabetes

2018-01-18 10:49:09 | BioPortfolio


A study is to see if methyldopa can change the immune system's attack on insulin producing cells in people at early stages of type 1 diabetes.


The study is a randomized, double blinded, placebo-controlled, multi-center crossover clinical trial.

Eligible subjects will be randomized in a 1:1 allocation ratio to one of two treatment schedules: first methyldopa then placebo vs. first placebo then methyldopa.

The study objective is to assess the safety, efficacy, and mode of action of methyldopa to reduce DQ8 antigen presentation in individuals at Stage 1 and 2 of type 1 diabetes (T1D).

Study Design


Type1 Diabetes Mellitus


Methyldopa, Placebo


Not yet recruiting


National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Results (where available)

View Results


Published on BioPortfolio: 2018-01-18T10:49:09-0500

Clinical Trials [3403 Associated Clinical Trials listed on BioPortfolio]

Using an Artificial Pancreas System in Older Adult Type 1 Diabetes Mellitus Patients

To demonstrate that a new insulin pump system can prevent low glucose episodes and improve brain function in aged Type 1 diabetes mellitus subjects.

Open Trial of Miglitol in Type 1 Diabetic Patients With Insulin Treatment

The purpose of this study is evaluate the clinical efficacy and safety of Miglitol in patients with Type1 Diabetes Mellitus treated with insulin.

Clinical Bioequivalence Study on Two Methyldopa Tablet 250mg Formulations

The objective of the study is to compare the bioavailability of a generic product of methyldopa with that of a reference product when administered to healthy volunteers under fasting condi...

Multiple Ascending Dose Study of HM12470 in Type 1 and Type 2 Diabetes Mellitus

This is a phase 1 multiple ascending dose (MAD) study, conducted in subjects with Type 1 and Type 2 diabetes mellitus

A Study of LY900014 Administered by an Insulin Pump in Type 1 Diabetes Participants

The study will be conducted in participants with type 1 diabetes mellitus to investigate how the human body processes LY900014, a new blood sugar lowering insulin, and its effect on blood ...

PubMed Articles [4727 Associated PubMed Articles listed on BioPortfolio]

Weekly glucagon-like peptide-1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study.

This phase 3, randomized, double-blind 24-week study with extension to 1 year assessed efficacy and safety of albiglutide compared with placebo in Japanese patients with type 2 diabetes mellitus (T2DM...

Effect of Aloe vera on glycemic outcomes in patients with diabetes mellitus: a systematic review protocol.

The objective is to identify the effectiveness of Aloe vera on glycemic outcomes (fasting blood glucose level and glycosylated hemoglobin) in patients with diabetes mellitus. Specifically, the review ...

Health-related quality-of-life implications of cardiovascular events in individuals with type 2 diabetes mellitus: A subanalysis from the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53 trial.

The impact of cardiovascular complications on health-related quality-of-life (HRQoL) in type 2 diabetes mellitus has not been clearly established. Using EQ5D utility data from SAVOR-TIMI 53, a large p...

Perinatal mortality in Japanese women diagnosed with gestational diabetes mellitus and diabetes mellitus.

The objective of this study was to determine how many pregnant Japanese women with diabetes mellitus (DM)/gestational diabetes mellitus (GDM) experience perinatal mortality in the presence of fetal an...

Beneficial Effects of n-3 Fatty Acids on Cardiometabolic and Inflammatory Markers in Type 2 Diabetes Mellitus: A Randomized Placebo-Controlled Double-blind Clinical Trial.

To determine the effect of n-3 polyunsaturated fatty acids (n-3PUFAs) supplementation on circulatory resistin and monocyte chemoattractant 1 (MCP-1) levels in type 2 diabetes mellitus (T2DM) patients.

Medical and Biotech [MESH] Definitions

A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.

Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY.

Urination of a large volume of urine with an increase in urinary frequency, commonly seen in diabetes (DIABETES MELLITUS; DIABETES INSIPIDUS).

A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.

A strain of Rattus norvegicus which is a model for spontaneous insulin-dependent diabetes mellitus (DIABETES MELLITUS, INSULIN-DEPENDENT).

More From BioPortfolio on "Methyldopa for Reduction of DQ8 Antigen Presentation in At-Risk Subjects for Type 1 Diabetes"

Quick Search


Searches Linking to this Trial